Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A review of 2014 cancer drug approvals, with a look at 2015 and beyond.

Literature DB >> 25798040

A review of 2014 cancer drug approvals, with a look at 2015 and beyond.

Taylor Butler, Stacey Maravent, Jennifer Boisselle, Jose Valdes, Chris Fellner.

Abstract

The number of cancer medications approved by the Food and Drug Administration has risen steadily in recent years. This article provides a concise overview of drugs and indications added to the cancer armamentarium in 2014 and to date in 2015.

Entities: Disease

Year: 2015 PMID： 25798040 PMCID： PMC4357352

Source DB: PubMed Journal: P T ISSN： 1052-1372

13 in total

1. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

Authors: Bella Kaufman; Ronnie Shapira-Frommer; Rita K Schmutzler; M William Audeh; Michael Friedlander; Judith Balmaña; Gillian Mitchell; Georgeta Fried; Salomon M Stemmer; Ayala Hubert; Ora Rosengarten; Mariana Steiner; Niklas Loman; Karin Bowen; Anitra Fielding; Susan M Domchek
Journal: J Clin Oncol Date: 2014-11-03 Impact factor: 44.544

2. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

Authors: Ajay K Gopal; Brad S Kahl; Sven de Vos; Nina D Wagner-Johnston; Stephen J Schuster; Wojciech J Jurczak; Ian W Flinn; Christopher R Flowers; Peter Martin; Andreas Viardot; Kristie A Blum; Andre H Goy; Andrew J Davies; Pier Luigi Zinzani; Martin Dreyling; Dave Johnson; Langdon L Miller; Leanne Holes; Daniel Li; Roger D Dansey; Wayne R Godfrey; Gilles A Salles
Journal: N Engl J Med Date: 2014-01-22 Impact factor: 91.245

3. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Authors: Max S Topp; Peter Kufer; Nicola Gökbuget; Mariele Goebeler; Matthias Klinger; Svenja Neumann; Heinz-A Horst; Thorsten Raff; Andreas Viardot; Mathias Schmid; Matthias Stelljes; Markus Schaich; Evelyn Degenhard; Rudolf Köhne-Volland; Monika Brüggemann; Oliver Ottmann; Heike Pfeifer; Thomas Burmeister; Dirk Nagorsen; Margit Schmidt; Ralf Lutterbuese; Carsten Reinhardt; Patrick A Baeuerle; Michael Kneba; Hermann Einsele; Gert Riethmüller; Dieter Hoelzer; Gerhard Zugmaier; Ralf C Bargou
Journal: J Clin Oncol Date: 2011-05-16 Impact factor: 44.544

4. Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization.

Authors: Kiyoshi Okamoto; Megumi Ikemori-Kawada; Anja Jestel; Konstanze von König; Yasuhiro Funahashi; Tomohiro Matsushima; Akihiko Tsuruoka; Atsushi Inoue; Junji Matsui
Journal: ACS Med Chem Lett Date: 2014-11-17 Impact factor: 4.345

5. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

Authors: Martin Schlumberger; Makoto Tahara; Lori J Wirth; Bruce Robinson; Marcia S Brose; Rossella Elisei; Mouhammed Amir Habra; Kate Newbold; Manisha H Shah; Ana O Hoff; Andrew G Gianoukakis; Naomi Kiyota; Matthew H Taylor; Sung-Bae Kim; Monika K Krzyzanowska; Corina E Dutcus; Begoña de las Heras; Junming Zhu; Steven I Sherman
Journal: N Engl J Med Date: 2015-02-12 Impact factor: 91.245

6. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

Authors: Charles S Fuchs; Jiri Tomasek; Cho Jae Yong; Filip Dumitru; Rodolfo Passalacqua; Chanchal Goswami; Howard Safran; Lucas Vieira Dos Santos; Giuseppe Aprile; David R Ferry; Bohuslav Melichar; Mustapha Tehfe; Eldar Topuzov; John Raymond Zalcberg; Ian Chau; William Campbell; Choondal Sivanandan; Joanna Pikiel; Minori Koshiji; Yanzhi Hsu; Astra M Liepa; Ling Gao; Jonathan D Schwartz; Josep Tabernero
Journal: Lancet Date: 2013-10-03 Impact factor: 79.321

7. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Authors: Edward B Garon; Tudor-Eliade Ciuleanu; Oscar Arrieta; Kumar Prabhash; Konstantinos N Syrigos; Tuncay Goksel; Keunchil Park; Vera Gorbunova; Ruben Dario Kowalyszyn; Joanna Pikiel; Grzegorz Czyzewicz; Sergey V Orlov; Conrad R Lewanski; Michael Thomas; Paolo Bidoli; Shaker Dakhil; Steven Gans; Joo-Hang Kim; Alexandru Grigorescu; Nina Karaseva; Martin Reck; Federico Cappuzzo; Ekaterine Alexandris; Andreas Sashegyi; Sergey Yurasov; Maurice Pérol
Journal: Lancet Date: 2014-06-02 Impact factor: 79.321

8. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Authors: Caroline Robert; Antoni Ribas; Jedd D Wolchok; F Stephen Hodi; Omid Hamid; Richard Kefford; Jeffrey S Weber; Anthony M Joshua; Wen-Jen Hwu; Tara C Gangadhar; Amita Patnaik; Roxana Dronca; Hassane Zarour; Richard W Joseph; Peter Boasberg; Bartosz Chmielowski; Christine Mateus; Michael A Postow; Kevin Gergich; Jeroen Elassaiss-Schaap; Xiaoyun Nicole Li; Robert Iannone; Scot W Ebbinghaus; S Peter Kang; Adil Daud
Journal: Lancet Date: 2014-07-15 Impact factor: 79.321

9. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Authors: Hansjochen Wilke; Kei Muro; Eric Van Cutsem; Sang-Cheul Oh; György Bodoky; Yasuhiro Shimada; Shuichi Hironaka; Naotoshi Sugimoto; Oleg Lipatov; Tae-You Kim; David Cunningham; Philippe Rougier; Yoshito Komatsu; Jaffer Ajani; Michael Emig; Roberto Carlesi; David Ferry; Kumari Chandrawansa; Jonathan D Schwartz; Atsushi Ohtsu
Journal: Lancet Oncol Date: 2014-09-17 Impact factor: 41.316

10. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Authors: Omid Hamid; Caroline Robert; Adil Daud; F Stephen Hodi; Wen-Jen Hwu; Richard Kefford; Jedd D Wolchok; Peter Hersey; Richard W Joseph; Jeffrey S Weber; Roxana Dronca; Tara C Gangadhar; Amita Patnaik; Hassane Zarour; Anthony M Joshua; Kevin Gergich; Jeroen Elassaiss-Schaap; Alain Algazi; Christine Mateus; Peter Boasberg; Paul C Tumeh; Bartosz Chmielowski; Scot W Ebbinghaus; Xiaoyun Nicole Li; S Peter Kang; Antoni Ribas
Journal: N Engl J Med Date: 2013-06-02 Impact factor: 91.245

7 in total

1. Making the right calls in precision oncology.

Authors: Kathryn D Bungartz; Kristen Lalowski; Sheryl K Elkin
Journal: Nat Biotechnol Date: 2018-08-06 Impact factor: 54.908

Review 2. A Review on Mechanistic Insight of Plant Derived Anticancer Bioactive Phytocompounds and Their Structure Activity Relationship.

Authors: Kishor Mazumder; Asma Aktar; Priyanka Roy; Biswajit Biswas; Md Emran Hossain; Kishore Kumar Sarkar; Sitesh Chandra Bachar; Firoj Ahmed; A S M Monjur-Al-Hossain; Koichi Fukase
Journal: Molecules Date: 2022-05-09 Impact factor: 4.927

6. Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas.

Authors: Yazan F Madanat; Mitchell R Smith; Alexandru Almasan; Brian T Hill
Journal: Blood Lymphat Cancer Date: 2016-03-15

Review 7. Plant-Derived Anticancer Agents: Lessons from the Pharmacology of Geniposide and Its Aglycone, Genipin.

Authors: Solomon Habtemariam; Giovanni Lentini
Journal: Biomedicines Date: 2018-03-26